Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency

ADAM17 (a disintegrin and metalloproteinase 17)/TACE (TNFα converting enzyme) has emerged as a potential therapeutic target in colorectal cancer (CRC) and other cancers, due in part to its role in regulating various tumor cell surface proteins and growth factors and cytokines in the tumor microenvir...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Dosch, Joseph, Ziemke, Elizabeth, Wan, Shanshan, Luker, Kathryn, Welling, Theodore, Hardiman, Karin, Fearon, Eric, Thomas, Suneetha, Flynn, Matthew, Rios-Doria, Jonathan, Hollingsworth, Robert, Herbst, Ronald, Hurt, Elaine, Sebolt-Leopold, Judith
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630314/
https://ncbi.nlm.nih.gov/pubmed/29029414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17780
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados